5,8-Dihydroxy-1-methyl-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2,4,6,8,10,13(20),15-heptaene-12,17-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 5,8-Dihydroxy-1-methyl-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2,4,6,8,10,13(20),15-heptaene-12,17-dione
• 化学式: C₂₀H₁₄O₅
• 分子量: 334.3
• InChiKey: WXLYRCGVTYXHMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  25
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• COMPOSITIONS AND INTRALUMINAL DEVICES FOR INHIBITING VASCULAR STENOSIS
  申请人：The Trustees of Columbia University in the City of New York

  公开号：EP2012794A2

  公开（公告）日：2009-01-14
• Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
  申请人：ANDERSEN Raymond J.

  公开号：US20090042868A1

  公开（公告）日：2009-02-12

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.
• METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA
  申请人：Marks Andrew R.

  公开号：US20090274739A1

  公开（公告）日：2009-11-05

  The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising delivery of such compositions or intraluminal devices to subjects in need thereof. The compositions, intraluminal devices, and methods of the invention are particularly well-suited for the treatment or prevention of vascular stenosis and restenosis in obese and diabetic subjects.
• US7799776B2
  申请人：——

  公开号：US7799776B2

  公开（公告）日：2010-09-21
• [EN] COMPOSITIONS AND INTRALUMINAL DEVICES FOR INHIBITING VASCULAR STENOSIS<br/>[FR] COMPOSITIONS ET DISPOSITIFS INTRALUMINAUX PERMETTANT D'INHIBER LA STENOSE VASCULAIRE
  申请人：UNIV COLUMBIA

  公开号：WO2007120897A2

  公开（公告）日：2007-10-25

  [EN] The present invention relates to compositions containing rapamycin or rapamycin derivative in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising delivery of such compositions or intraluminal devices to subjects in need thereof. The compositions, intraluminal devices, and methods of the invention are particularly well-suited for the treatment or prevention of vascular stenosis and restenosis in obese and diabetic subjects.
  [FR] L'invention concerne des compositions contenant de la rapamycine ou un dérivé de la rapamycine en combinaison avec un inhibiteur de la kinase PI3 et/ou avec un inhibiteur de la leptine, sur des dispositifs intraluminaux configurés pour libérer de telles compositions et sur des procédés permettant le traitement et/ou la prévention de l'hyperplasie intime, de la sténose et/ou de la resténose vasculaire comprenant l'administration de telles compositions ou dispositifs intraluminaux aux sujets en ayant. Les compositions, dispositifs intraluminaux et procédés de l'invention sont particulièrement bien adaptés au traitement ou à la prévention de la sténose vasculaire et de la resténose vasculaire chez des sujets obèses et diabétiques.